PDF(Pubmed)
Abstract：
UNASSIGNED: To address the problem of suboptimal reactive oxygen species (ROS) production in Radiation therapy (RT) which was resulted from exacerbated tumor hypoxia and the heterogeneous distribution of radiation sensitizers.
UNASSIGNED: In this work, a novel nanomedicine, designated as PLGA@IR780-Bi-DTPA (PIBD), was engineered by loading the radiation sensitizer Bi-DTPA and the photothermal agent IR780 onto poly(lactic-co-glycolic acid) (PLGA). This design leverages the tumor-targeting ability of IR780 to ensure selective accumulation of the nanoparticles in tumor cells, particularly within the mitochondria. The effect of the photothermal therapy-enhanced radiation therapy was also examined to assess the alleviation of hypoxia and the enhancement of radiation sensitivity.
UNASSIGNED: The PIBD nanoparticles exhibited strong capacity in mitochondrial targeting and selective tumor accumulation. Upon activation by 808 nm laser irradiation, the nanoparticles effectively alleviated local hypoxia by photothermal effect enhanced blood supplying to improve oxygen content, thereby enhancing the ROS production for effective RT. Comparative studies revealed that PIBD-induced RT significantly outperformed conventional RT in treating hypoxic tumors.
UNASSIGNED: This design of tumor-targeting photothermal therapy-enhanced radiation therapy nanomedicine would advance the development of targeted drug delivery system for effective RT regardless of hypoxic microenvironment.
UNASSIGNED: In this work, a novel nanomedicine, designated as PLGA@IR780-Bi-DTPA (PIBD), was engineered by loading the radiation sensitizer Bi-DTPA and the photothermal agent IR780 onto poly(lactic-co-glycolic acid) (PLGA). This design leverages the tumor-targeting ability of IR780 to ensure selective accumulation of the nanoparticles in tumor cells, particularly within the mitochondria. The effect of the photothermal therapy-enhanced radiation therapy was also examined to assess the alleviation of hypoxia and the enhancement of radiation sensitivity.
UNASSIGNED: The PIBD nanoparticles exhibited strong capacity in mitochondrial targeting and selective tumor accumulation. Upon activation by 808 nm laser irradiation, the nanoparticles effectively alleviated local hypoxia by photothermal effect enhanced blood supplying to improve oxygen content, thereby enhancing the ROS production for effective RT. Comparative studies revealed that PIBD-induced RT significantly outperformed conventional RT in treating hypoxic tumors.
UNASSIGNED: This design of tumor-targeting photothermal therapy-enhanced radiation therapy nanomedicine would advance the development of targeted drug delivery system for effective RT regardless of hypoxic microenvironment.
摘要：
■为了解决放射治疗（RT）中不良活性氧（ROS）产生的问题，这是由于加剧的肿瘤缺氧和辐射敏化剂的异质分布所致。
■在这项工作中，一种新的纳米医学，指定为PLGA@IR780-Bi-DTPA（PIBD），通过将辐射敏化剂Bi-DTPA和光热剂IR780加载到聚(乳酸-共-乙醇酸)(PLGA)上而设计。这种设计利用了IR780的肿瘤靶向能力，以确保纳米颗粒在肿瘤细胞中的选择性积累，特别是在线粒体内。还检查了光热疗法增强的放射疗法的效果，以评估缺氧的减轻和辐射敏感性的增强。
■PIBD纳米颗粒在线粒体靶向和选择性肿瘤积累方面表现出很强的能力。通过808nm激光照射激活后，纳米粒子通过光热效应有效缓解局部缺氧，增强血液供应，提高氧含量，从而提高ROS的产生以获得有效的RT。比较研究表明，PIBD诱导的RT在治疗缺氧肿瘤方面明显优于常规RT。
■这种肿瘤靶向光热疗法增强放射治疗纳米医学的设计将促进靶向药物递送系统的开发，无论缺氧微环境如何，都可以有效地进行RT。
■在这项工作中，一种新的纳米医学，指定为PLGA@IR780-Bi-DTPA（PIBD），通过将辐射敏化剂Bi-DTPA和光热剂IR780加载到聚(乳酸-共-乙醇酸)(PLGA)上而设计。这种设计利用了IR780的肿瘤靶向能力，以确保纳米颗粒在肿瘤细胞中的选择性积累，特别是在线粒体内。还检查了光热疗法增强的放射疗法的效果，以评估缺氧的减轻和辐射敏感性的增强。
■PIBD纳米颗粒在线粒体靶向和选择性肿瘤积累方面表现出很强的能力。通过808nm激光照射激活后，纳米粒子通过光热效应有效缓解局部缺氧，增强血液供应，提高氧含量，从而提高ROS的产生以获得有效的RT。比较研究表明，PIBD诱导的RT在治疗缺氧肿瘤方面明显优于常规RT。
■这种肿瘤靶向光热疗法增强放射治疗纳米医学的设计将促进靶向药物递送系统的开发，无论缺氧微环境如何，都可以有效地进行RT。
